Press Releases Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
397.5 ^USD	-0.06%		+0.81%	-2.31%

Apr. 26	Vertex Pharmaceuticals Gets European Commission Approval for Cystic Fibrosis Treatment for Infants	MT
Apr. 26	Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older	Apr. 26	BU
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES	Apr. 23	PR
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES	Apr. 23	AQ
Vertex Announces Advancements of Suzetrigine in Acute and Neuropathic Pain	Apr. 19	AQ
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain	Apr. 18	BU
Vertex Pharma scientist talks about the long road to developing non-addictive painkillers	Apr. 15	AQ
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences	Apr. 10	BU
Vertex to Announce First Quarter 2024 Financial Results on May 6	Apr. 09	BU
Vertex Advances Inaxaplin into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease	Apr. 02	AQ
Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	Apr. 01	AQ
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease	Apr. 01	BU
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey	Mar. 28	AQ
InvestorBrandMedia: FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease"	Mar. 25	AQ
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	Mar. 22	AQ
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Mar. 21	BU
Vertex Pharmaceuticals Incorporated : ID&E Fact Sheet	Mar. 04	PU
Vertex Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older	Feb. 26	AQ
Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older	Feb. 23	BU
Vertex to Participate in Upcoming Investor Conferences	Feb. 20	BU
Cystic Fibrosis Pipeline Insights Report 2024 \| Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, and others.	Feb. 19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease

December 11, 2023 at 05:47 am EST